Paris 2026: Pioneering the Future of Cannabinoid Medicine

A Transformative Symposium in Paris

The Third Annual Science in the City International - Paris 2026, orchestrated by the Medical Resource Association, is set to be a landmark event in the realm of cannabinoid therapeutics. This symposium, focusing on the advancement of cannabinoid medicine, physician education, and clinical integration, arrives at a pivotal juncture for France. As the nation moves toward a permanent framework for medical cannabis, the event will play a crucial role in shaping the future of medical cannabis in France and Europe.

The choice of Paris as the venue underscores the city's emergence as a leading hub for pharmaceutical innovation and cannabinoid therapeutics. Previously hosted in Bordeaux, the decision to expand to Paris reflects the critical importance of this city, not only for France but for the wider European context. Paris stands out as a natural meeting point for regulators, clinicians, researchers, and industry leaders, all united in the mission to promote evidence-based medicine and ensure responsible patient access.

Convergence of Global Leaders

The symposium will gather an expert faculty comprising physicians, researchers, prescribers, pharmacists, healthcare executives, regulators, industry innovators, and patient advocates. These leaders will engage in discussions that will examine the future of pharmaceutical innovation, emerging therapeutics, and the advancement of evidence-based cannabinoid medicine across Europe. As healthcare and life sciences undergo transformative changes, the symposium provides a platform to explore the impact of pharmaceutical medicine, precision health, and plant-based medicine on healthcare delivery.

Charles S. Messal, COO of the Medical Resource Association, emphasizes the significance of collaboration and scientific exchange, stating, "The remarkable response to our Bordeaux editions showed that the global healthcare community is seeking a forum where science meets execution and collaboration drives innovation." This sentiment highlights the symposium's role in fostering a collaborative environment where cross-border innovation is not only encouraged but necessary for the continued progression of healthcare.

Global Reach and Impact

In addition to the Paris-based activities, the symposium will extend its reach globally through a "Live from New York" simulcast. This initiative aims to connect international audiences, thereby strengthening scientific exchange and collaboration across borders. Timothy L. Beury, CFO of the Medical Resource Association, notes the timely nature of the symposium as France advances its medical cannabis framework, underscoring the importance of such international collaboration.

Kristen M. Beury, Founder and CEO of the Medical Resource Association, articulates the broader vision of the event, "Science in the City International - Paris 2026 is more than a symposium; it is a convening of the individuals and institutions committed to advancing evidence-based medicine, physician education, and responsible patient access." This gathering in Paris represents a historic moment, bringing together the global community to push the boundaries of medical cannabis and pharmaceutical innovation.

Registration is now open for this transformative event, inviting participation from physicians, researchers, pharmacists, healthcare executives, regulators, industry innovators, and patient advocates. For more information or to register, interested parties can contact Charles Stéphane Messal via email or through the provided contact numbers.